Clinical Trial Update: Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 study of SPI-2012 or Pegfilgrastim for managing neutropenia in breast cancer has completed; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Neutropenia

Drugs mentioned

• Pegfilgrastim (pegfilgrastim)
• SPI-2012 (null)

Snippet

Sponsor: Spectrum Pharmaceuticals, Inc | Conditions: Neutropenia | Phase 2 | Status: COMPLETED | Results posted: 2022-04-15